Parabilis presents first-ever clinical evidence for FOG-001, a cancer therapy.

PD-1 Post # 13 Two Weeks Later: What Lilly's SERD ( Selective Estrogen Receptor Degrader ) Approval Really Tells Us About the Future of I-O Strategy The headlines around Lilly’s Inluriyo approval have rightly focused on its clinical impact for breast cancer patients. But a few week later, I believe its true significance lies in what it signals for the future of oncology strategy. Inluriyo’s success, guided by its companion diagnostic, confirms we are fully in a "diagnosis-driven development era." This resonates deeply with my own experience. Years ago, developing Antican, we used DRA technology to achieve real-time precision — treating only the patients who responded on 24-hour pathological slices. That "treat-or-don't-treat" clarity was key. Now, this precision mindset must evolve to combination therapies. Because precision targeting has reached diminishing returns — it’s time to make the backbone smarter. The next great leap in I-O won't just come from finding a new target. It will come from creating smarter, safer combinations for our existing powerful drugs, like PD-1 inhibitors. When you can amplify a proven backbone therapy like PD-1 without adding toxicity, you unlock the true potential of "Precision Combination." You're not just adding another drug; you are creating a new, superior standard of care. Lilly's milestone is a signpost for where oncology is heading. The next leader will be the one who masters not just precision targeting, but precision combination. Congratulations to the Lilly team. For the rest of us, the race for the next strategic frontier has just begun. #PrecisionMedicine #OncologyStrategy #PharmaStrategy #DrugDevelopment #PD1 #CombinationTherapy

🔬 Smarter T-cell Engagers for Solid Tumors Exciting progress from the AstraZeneca team! T-cell engagers (#TCEs) can redirect a patient’s own T cells to kill cancer cells — a concept already proven in blood cancers. But applying TCEs to solid tumors has been challenging, as many tumor antigens are also found on healthy tissues, leading to on-target, off-tumor toxicity. AstraZeneca scientists recently developed a novel trispecific TCE platform, TriMab, using an “AND-gate” logic to solve this issue. TriMab activates T cells only when two tumor antigens are present, ensuring precise targeting while sparing normal cells. In preclinical studies, a ROR1/EGFR TriMab showed: ✅ >500× higher killing of dual-positive tumor cells ✅ Reduced cytokine release ✅ Potent in vivo efficacy ✅ mAb-like stability and PK This modular platform could be applied to various solid tumors, paving the way for safer, smarter immunotherapies. Reference: https://lnkd.in/ejpG3A7y #Immunotherapy #Oncology #CancerResearch #TCE #Biologics #AstraZeneca #TriMab #AntibodyEngineering #Biotech #DrugDiscovery

🚀 Asia-Pacific Oncology Molecular Diagnostics on the Rise Get to Know More: https://lnkd.in/dgA3wzgV The demand for precision medicine and early cancer detection is transforming the oncology diagnostics landscape across Asia-Pacific. 🌏 🔬 Oncology molecular diagnostics enable faster, more accurate cancer detection and personalized treatment strategies — driving improved patient outcomes and advancing healthcare innovation. 📊 Market Snapshot: - 2023: US$ 0.71 billion - 2031: US$ 1.26 billion - CAGR: 7.50% With growing awareness, government initiatives, and technological innovation, the region is set to witness robust growth in oncology diagnostics adoption. https://lnkd.in/dHvuG4uk Major players included in the Asia-Pacific Oncology Molecular Diagnostics Market: F. Hoffmann-La Roche AG bioMérieux Abbott QIAGEN Illumina Danaher Corporation Agilent Technologies Sysmex Corporation Siemens Healthcare Pvt. Ltd. Diasorin #Oncology #MolecularDiagnostics #HealthcareInnovation #AsiaPacific #PrecisionMedicine #CancerDiagnostics

🎗️ October is #BreastCancerAwarenessMonth   Our analysts have been hard at work uncovering the latest insights shaping breast cancer research and treatment. Introducing The Breast Cancer Drug Development Landscape Report - a deep dive into the evolving therapeutic strategies, clinical activity, deal-making trends, and the companies driving innovation in this critical area.   🔍 Inside the report: • Clinical Trial Activity: Explore biomarkers driving the highest volume of trials, analyzed by phase • Drug Development Trends: Discover the most actively pursued therapeutic targets shaping next-generation therapies • Emerging Therapeutics & FDA Updates: Stay informed on recent breakthroughs and approvals transforming patient care • Deals & Licensing Insights: Track market-shaping deals and licensing activity defining the 2025 landscape   Download the full report: https://ter.li/g3ycu5   #BreastCancer #BreastCancerAwareness #DrugDevelopment #ClinicalTrials #ClinicalDevelopment #LifeSciences

🚀 Farcast: Translating Models into Meaningful Oncology Insights Our validated, publication-backed platform of clinically relevant cancer models spans a wide spectrum of oncology indications (See image below 👇) — designed to reflect real patient diversity and disease complexity.   🧬 More than just models — actionable insight. Backed by peer-reviewed publications and scientific posters showcased at global conferences like AACR and SITC, our models don’t just mimic disease. They help: ✅ Predict therapeutic response ✅ Uncover resistance mechanisms ✅ Identify and validate biomarkers 🤝 We work closely with biotech and pharma partners to drive smarter, faster decisions in oncology drug development — powered by data, not assumptions.   📄 Curious to see our models in action? Explore our latest posters, publications, and indication-specific data here: https://lnkd.in/g4Kb8uw #OncologyModels #CancerResearch #PreclinicalOncology #BiotechInnovation #Farcast #TranslationalScience #DrugDevelopment #ImmunoOncology #AACR #SITC

📊 Final Data     Percheron Therapeutics Limited has announced final data from the phase I clinical trial of HMBD-002, a novel therapy under development for multiple forms of cancer.    The phase I trial was completed across six US centres under FDA IND oversight, enrolling 48 patients with advanced, heavily pre-treated cancers (including pancreas, bowel, breast, lung and others).    Key outcomes include:   ➡️ HMBD-002 showed a favourable safety profile at doses up to 1,400mg/week, alone or with Keytruda®. <10% experienced grade ≥3 treatment-related events, and no maximum tolerated dose was reached.  ➡️ While focused on safety, the study also saw signs of benefit in multiple tumour types.  ➡️ Results will guide a planned Phase II efficacy trial in 2026, with data targeted for journal publication that year.    Percheron CEO, Dr James Garner commented:     “We are delighted to see final data from the HMBD-002 phase I study. These data are very encouraging as we look toward a phase II trial next year. In particular, the data confirms the excellent safety profile of HMBD-002, which has the potential to be best-in-class, and it also provides some tantalising glimpses of potential efficacy. We are immensely grateful to the dedicated clinicians who worked on the study, and to the patients and families who participated.”    Read the ASX release 👉 https://bit.ly/3IWaBLP     $PER #Percheron #oncology #clinicaltrial #innovation #biotech #ASX   

The first fully automated, cartridge-based, sample-to-result U.S. CDx! I'm happy to share that FDA has granted PMA to the Idylla™ CDx MSI Test, developed with BMS, which will help physicians quickly identify MSI-H CRC patients eligible for OPDIVO (nivolumab) alone or with YERVOY (ipilimumab). This milestone reflects the maturity of our quality, clinical, regulatory, manufacturing, marketing, development and partnership functions. I'm proud to work with such a great team. Stay tuned for much more to come! One final note: The Biocartis Corporate & Business Development team is actively partnering with world-class pharma, academic and industry leaders to bring new high-value content to the Idylla™ platform. Think SNVs, fusions, indels, gene expression signatures, methylation, liquid biopsy, early detection, cell therapy monitoring and more. With over 2,500 instruments placed in laboratories worldwide, Idylla™ is becoming the go-to platform for bringing high-value genomics testing into the heart of the precision oncology ecosystem. DM me or Mike Kreitzinger if you have partnership ideas to explore. #MSI #CDx #FDA #PMA #BMS #ColorectalCancer #Oncology #Idylla

Get your fully cell line based (NO PLASMIDS) MSI FFPE Reference Set at SensID today. A qualitative control for the Idylla™ MSI Assay. https://lnkd.in/dMjSD49b We also have available an RUO version of this product: https://lnkd.in/dHS_Q9J5 Intended use of the RUO product: MSI FFPE Reference Set is intended as commutable, qualitative control material for microsatellite instability (MSI) markers in FFPE format based on human cell lines. It consists of MSI FFPE MSI-H control with all MSI markers and MSI FFPE MSS control with 0% frequency for all MSI markers. This Reference set enables monitoring of the performance, procedures and workflow of laboratory tests using FFPE in combination with the extraction workflows.

Unlock the 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫 𝐜𝐡𝐞𝐦𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐰𝐢𝐭𝐡 𝐞𝐱𝐨𝐬𝐨𝐦𝐞-𝐛𝐚𝐬𝐞𝐝 𝐝𝐫𝐮𝐠 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲 — a revolutionary leap in precision medicine. In their latest research, Disha Marwaha, Assistant Professor, GLA University and Neha Singh Assistant Professor, Lloyd School of Pharmacy illuminate how these tiny vesicles, once dismissed as cellular waste, are now transforming targeted cancer therapies by enhancing drug stability, reducing toxicity, and enabling personalized treatment strategies. Engineered exosomes promise safer, more effective chemotherapy with minimized side effects and improved patient outcomes. Explore how innovation in exosome engineering is reshaping oncology, clinical trials, and drug discovery pipelines. Stay ahead in pharma by integrating these cutting-edge insights into your R&D and therapeutic approaches. 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐛𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐚𝐧𝐝 𝐣𝐨𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐚𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐜𝐚𝐫𝐞: https://lnkd.in/gQ6rKzUS #PharmaceuticalInnovation #PrecisionMedicine #CancerTherapy #DrugDelivery #Exosomes #ClinicalTrials #OncologyResearch #Biotech #PharmaR&D #PersonalizedMedicine #DigitalHealth #PharmaTrends #HealthcareInnovation #TargetedTherapies #FutureOfMedicine #PharmaFocus

🚨 The Hard Truth in NSCLC One non-small cell lung cancer tumor is never just one disease. RNA-seq shows multiple oncogenic drivers — KRAS, EGFR, MET, ALK — all active in the same patient. That complexity has real consequences: ✔️Drugs built for a single mutation often collapse. ✔️Backup pathways take over. ✔️Resistance sets in. ✔️The result: 90% failure rate in oncology trials. Pharma invests billions, but PDOs, PDXs, and engineered lines can’t capture this heterogeneity. 💡 Omicue GNGS closes the gap. We test drugs directly on live patient tumor cells, capturing both morphology and transcriptomics: ✔️ Clinicians see if proliferation and immune suppression truly shut down. ✔️ Pharma sees early which molecules are worth advancing — and which to drop before Phase I. 👉 If you care about stopping drug attrition in lung cancer, and ensuring the right patients get the right drugs, let’s connect. #LungCancer #Oncology #DrugDiscovery #PrecisionMedicine #PharmaInnovation #ClinicalTrials #Omicue #Pfizer #Novartis #Roche #Janssen #Merck #Sanofi #BristolMyersSquibb #GSK #AstraZeneca #EliLilly